Loading...
You have changed your country from
to
. Please be aware that this will change the currency in the purchasing process.
Related products
- Primary antibodies
Reassurance, Refunds & Replacements
If your product does not perform as described on this datasheet, we will refund or replace your product...
Read our guarantee »Overview
Product name
XIAP peptide
See all XIAP products (4) ...
Protein description
13 amino acids near the carboxy terminus of human XIAP. This peptide was used as an immunogen for ab21278 - XIAP antibody.
Properties
Purification notes
60-70% purity.
Biological activity
Blocking the activity of Anti-XIAP antibody
Form
Liquid
Storage instructions
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Storage buffer
Preservative: 0.02% Sodium Azide
Constituents: 0.1% BSA, PBS, pH 7.2
Concentration
Concentration information loading...
Research areas
Metabolism >> Pathways and Processes >> Metabolism processes >> Apoptosis
Cancer >> Invasion/microenvironment >> Apoptosis >> Death receptors & ligands >> IAPs
Cancer >> Invasion/microenvironment >> Apoptosis >> Caspases
Cell Biology >> Apoptosis >> Intracellular >> Caspases etc >> Inhibitors
Cell Biology >> Apoptosis >> Intracellular >> Survivin / IAPs
Applications
Show applications key
Our Abpromise guarantee covers the use of ab41843 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Blocking
Application notes
BL: Use at an assay dependent dilution.
This peptide usually blocks the antibody activity completely in immunoblots by incubating the peptide with equal volume of antibody for 30 min at 37°C.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
Protein info
Function
Apoptotic suppressor. Has E3 ubiquitin-protein ligase activity. Mediates the proteasomal degradation of target proteins, such as caspase-3, SMAC or AIFM1. Inhibitor of caspase-3, -7 and -9. Mediates activation of MAP3K7/TAK1, leading to the activation of NF-kappa-B.
Tissue specificity
Ubiquitous, except peripheral blood leukocytes.
Involvement in disease
Defects in XIAP are the cause of lymphoproliferative syndrome X-linked type 2 (XLP2) [MIM:300635]. XLP is a rare immunodeficiency characterized by extreme susceptibility to infection with Epstein-Barr virus (EBV). Symptoms include severe or fatal mononucleosis, acquired hypogammaglobulinemia, pancytopenia and malignant lymphoma.
Sequence similarities
Belongs to the IAP family.
Contains 3 BIR repeats.
Contains 1 RING-type zinc finger.
Domain
The first BIR domain is involved in interaction with TAB1/MAP3K7IP1 and is important for dimerization. The second BIR domain is sufficient to inhibit caspase-3 and caspase-7, while the third BIR is involved in caspase-9 inhibition. The interactions with SMAC and PRSS25 are mediated by the second and third BIR domains.
Post-translational
modifications
Ubiquitinated and degraded by the proteasome in apoptotic cells.
Phosphorylation by PKB/AKT protects XIAP against ubiquitination and protects the protein against proteasomal degradation.
Cellular localization
Cytoplasm.
Target information above from: UniProt accessionP98170
The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010).
References for XIAP peptide (ab41843)
ab41843 has not yet been referenced specifically in any publications.
Publishing research using ab41843? Please let us know so that we can cite the reference in this datasheet
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"